Immune Design, an early-stage biotech developing immunotherapy cancer treatments, filed on Monday with the SEC to raise up to $60 million in an initial public offering. The Seattle, WA-based company, which was founded in 2008 and booked $1.1 million in licensing and product sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol IMDZ. Immune Design initially filed confidentially on 4/24/2014. Jefferies & Co., and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
